<DOC>
	<DOCNO>NCT02679170</DOCNO>
	<brief_summary>Prospective Observational Study To Identify Patients With Advanced/metastatic Non Small Cell Lung Cancer ( NSCLC ) And ALK Translocation And To Establish Their Therapeutic Management clinical practice ( IDEALK )</brief_summary>
	<brief_title>Prospective Observational Study To Identify Patients With Advanced/Metastatic Non Small Cell Lung Cancer ( NSCLC ) And ALK Translocation And To Establish Their Therapeutic Management ( IDEALK )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Patients Advanced metastatic nonsmall cell lung cancer Patients screen anaplastic lymphoma kinase ( ALK ) rearrangement Age &gt; 18 year For patient recruit prospectively : Patients must sign informed consent document . For treatment substudy , patient must also meet follow criterion Confirmed anaplastic lymphoma kinase ( ALK ) positive tumour Patients treat crizotinib routine clinical practice Patients minimum data register medical history Any patient meet inclusion criterion define previous section , depend substudy include .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ALK+</keyword>
</DOC>